Tacrolimus의 LC/MS 분석과 지원자에 대한 약물동태 연구

윤민혁,이서판,남진경,권광일 忠南大學校 生命科學硏究院 醫藥品開發硏究所 2006 藥學論文集 Vol.21 No.-

The purpose of this study was to confirm the analysis method and also to estimate the pharmacokinetic parameters of tacrolimus in human volunteers. The pharmacokinetics of tacrolimus tablet was examined on 24 healthy volunteers who received a single oral dose(4mg) of each preparation in the fasting state. After an oral dosing, blood samples were collected for a period of 72 hours. Blood concentrations of tacrolimus were determined using a liquid chromatographic electrospray mass spectrometric (LC-MS) method. The pharmacokinetic parameters were calculated with non-compartmental(AUC, C_(max), T_(max), Cl_(t), V/F) and compartmental(K_(el), K_(a), K_(12), K_(21), t_(1/2)) pharmacokinetic analysis using WinNonlin program. The estimated means of AUC_(0-72hours), C_(max) and T_(max) were 425.54 ± 197.49 ng·hr/ml, 76.14 ± 29.18 ng/ml and 1.40 ± 0.44 hr, respectively. The means of other pharmacokinetic parameters(V/F, CL_(t), K_(el), K_(a), K_(23), K_(32) and t_(1/2)) were 35.12 ± 34.28 L, 10.45 ± 5.32 L/hr, 0.39 ± 0.21 hr^(-1), 1.91 ± 4.17 hr^(-1), 0.32 ± 0.33 hr^(-1), 0.07 ± 0.09 hr^(-1), 26.94 ± 10.19 hr^(-1), respectively.

일측성 질폐쇄 및 동측 신장 무발생을 동반한 중복자궁 2예

윤일영,여소진,김형문,김정식,김태희,이해혁,남계현,이권해,김준모,김민의 순천향의학연구소 2004 Journal of Soonchunhyang Medical Science Vol.10 No.2

Uterus didelphys with unilateral obstructed hemivagina and ipsilateral renal agenesis usually presents after menarch with progressive abdominal pain during menses secondary to hematocolpos, and indeed a very rare congenital anomaly due to Mullerian duct malformation. An accurate and prompt diagnosis is of importance to permit treatment and to assure the future fertility of the patient. Pelvic ultrasound, physical examination and pelvic MRI established a diagnosis of hematometracolpos secondary to uterus didelphys with unilateral imperforate hemivagina. An incision in the vaginal septum allowed drainage of the hematocolpos, providing relief of the patients symptoms. We report two case of uterus didelphys with obstructed hemivagina with brief review of the literature.

A Study on the Miniaturization of a Protective Device for the Micro Smart Grid Simulator

Yun‑Seok Ko,Kyung Ryu,Min‑Soo Oh,Hyuk‑Sik Yoon 대한전기학회 2020 Journal of Electrical Engineering & Technology Vol.15 No.1

In this paper, a miniaturization methodology of protective devices (PDs) was proposed which plays a key role in evaluating the efectiveness of the developed protection and control algorithms in the micro smart grid simulator. The micro PD was designed to have the rated voltage of 19 V and the breaking current of 20 A, and was designed in a multi-layered hardware structure to satisfy the size of 13×13 cm2 . Also, the micro PD was designed in a multifunctional structure to allow one micro PD to perform all the functions of the circuit breaker, recloser and switches on the micro smart grid simulator to enhance the efciency of development. Finally, it was verifed that the developed micro PD can be applied as protective devices of the micro smart grid simulator by showing that it operates correctly according to the predetermined operation sequence for the test scenarios on the built test system.

철근콘크리트 보의 2단주근 부착할렬거동에 관한 실험적 연구

김혜민,이형복,강호근,윤혁기 慶南專門大學 2001 論文集 Vol.29 No.1

퀴니딘 정제의 건강한 한국인에 대한 약물동태

박희찬,윤민혁,김동출,권준택,권광일 충남대학교 약학대학 의약품개발연구소 2004 藥學論文集 Vol.19 No.-

The purpose of this study was to estimate the pharmacokinetics of quinidine sulfate in healthy Korean The parameters were examined on 16 volunteers who received a oral single dose(200mg quinidine sulfate). After dosing. blood samples were collected for a period of 24 hours. Plasma samples were analyzed for quinidine sulfate and DL-propranolol hydrochloride(internal standard) by HPLC/UV. The pharmacokinetic parameters (AUC_(0-24hr), AUC_(inf). C_(max), T_(max), K_(a), K_(el), t_(1/2), Vd/F and Cl/F) were calculated from the plasma quinidine sulfate concentration-time data of each volunteer. The computer program "WinNonlin" was used for compartmental analysis. One compartment model with first order input, first order output was chosen as the appropriate pharmacokinetic model. The pharmacokinetic parameters(AUC_(0-24hr). AUC_(inf). C_(max), T_(max), K_(a), K_(el), T_(1/2), Vd/F and Cl/F) calculated 9.47±2.24 ㎍·hr·㎖^(-1), 10.95±2.62 ㎍·hr·㎖^(-1), 0.93±0.16 ㎍/㎖, 1.56±0.45 hr, 1.10±0.36 hr^(-1), 5.17+0.90 hr, 162.38±33.36 L and 22.27±5.35 L/hr, respectively.

LC/MS/MS 분석법을 이용한 Amlodipine의 약물동태연구

서정원,윤민혁,강원구,권광일 충남대학교 약학대학 의약품개발연구소 2007 藥學論文集 Vol.22 No.-

The aim of this study were to confirm the analysis method and also to estimate the pharmacokinetic parameters of amlodipine in human volunteers. In an open-label single-dose pharmacokinetic study, a group, consisting of 24 healthy volunteers, received single oral dose of 5mg amlodipine. Blood sample were taken for up to 120 hours. The concentration of amlodipine in these body fluids was determinated using a validated high-performance liquid chromatography(HPLC) method with tandem mass spectrometry. Amlodipine and ketoconazole, an internal standard, were extracted from plasma using ethyl acetate in the presence of 0.1M sodium carbonate. After drying the organic layer, the residue was reconstituted in mobile phase(acetonitrile : water = 70 : 30 v/v (0.1% formic acid)) and injected onto a Zorvax C18 column (2.1 × 100 mm, 3.5 ㎛ particles). The isocratic mobile phase was eluted at 0.2ml/min. The ion transitions monitored in multiple reaction-monitoring mode were m/z 410.10 → 294.95 and 532.11 → 81.95, respectively. The coefficient of variance of the assay precision was less than 12%, and the accuracy exceeded 99.1%. The limit of quantification was 0.1 ng/ml. The pharmacokinetic parameters were calculated with non-compartmental(AUC, C_(max), T_(max), CL_(t), V/F) and compartmental(K_(el), K_(a), t_(lag)) pharmacokinetic analysis using WinNonlin program. The estimated means of AUC_(0-120hr), C_(max) and T_(max) were 196.90 ± 5.02 ng·hr/ml, 3.36 ± 0.09 ng/ml and 10.44 ± 0.61 hr, respectively. The means of other pharmacokinetic parameters(V/F, CL_(t), K_(el), K_(a) and t_(lag)) were 1208.06 ± 50.61 L, 25.39 ± 0.65 L/hr, 0.2806 ± 0.0294 hr^(-1), 0.0210 ± 0.0008 hr-1 and 0.4574 ± 0.0635 hours, respectively.

인체에서 carvedilol의 심혈관계 작용에 대한 PK/PD modeling

백인환,윤민혁,윤휘열,남진경,권광일 충남대학교 약학대학 의약품개발연구소 2007 藥學論文集 Vol.22 No.-

The objective of the present study was to determine and characterize the relationship between the cardiovascular effect and plasma concentration of carvedilol by PK/PD modeling in human. A group of 32 healthy males received oral doses of 25 mg carvedilol, and blood samples were collected thirteen times for up to 30 hours after the drug administration. The effect of carvedilol on blood pressure was measured during the same period. This experiment was analyzed using the liquid-liquid extractions of carvedilol by HPLC with fluorescence detection. Pharmacokinetics parameters of carvedilol were calculated using the two-compartment model with first-order absorption. The average value of C_(max), T_(max), CL/F (apparent clearance), V/F (apparent volume of distribution) and half-life of carvedilol were 62.74 ± 20.12 ng/ml, 1.26 ± 0.86 hrs, 94.64 ± 46.01 L/hr, 1561.78 ± 941.94 L, 12.47 hr, respectively. To explain the relationship between the cardiovascular effect and plasma concentration of carvedilol, plasma drug concentrations were linked to the observed SBP and DBP via a effect compartment with a sigmoid Emax model. The model parameters were estimated by using ADAPT Ⅱ program. This PK/PD model could describe the relationship between plasma concentrations of carvedilol and cardiovascular effect such as the aspects of decreasing blood pressure and the time delay between plasma concentration and pharmaco-dynamic data.

스트럿-타이 모델을 이용한 철근콘크리트 구조물의 구조해석 프로그램에 관한 연구

이형복,김혜민,윤혁기 慶南專門大學 1999 論文集 Vol.27 No.1

중증 외상환자에서 염기 결핍수치의 유용성

문준동,김수진,문철규,최성혁,전정민,이성우,홍윤식 대한응급의학회 2001 대한응급의학회지 Vol.12 No.3

Background: This study's objective was to determine the prognostic value of the base deficit measured in the emergency department(ED) and to determine whether base deficit can provide information not provided by advanced injury scoring system. Methods: This study was a retrospective analysis of data collected for two years. Thirty-two severe trauma patients who were admitted to the Emergency Department of Korea University Hospital were included in this study. The patients were divided into two groups: the normal base deficit group(-3 mmol/L to 3 mmol/L) and the elevated base deficit group(>3 mmol/L). The base-deficit value, age, sex, head injury, organ failure rate, and survival were considered, and the also Revised Trauma Score(RTS), Acute Physiology And Chronic Health Evaluation(APACHE II), and Injury Severity Score(ISS) were measured. Result: The elevated base-deficit group showed a lower survival rate and a higher organ failure rate compared to the normal base deficit group. Logistic Regression showed a strong association between base deficit and mortality rate. Among the previous injury scoring Systems(RTS, APACHE II, ISS), base deficit had the strongest correlation with RTS. By using base deficit value and the RTS together, we obtained a higher positive predictive value than that obtained by using base deficit or RTS alone. Conclusion: The admission value of the base deficit in the ED is a useful tool in predicting the outcome in severe trauma patients, and it can be an adjunct to previous injury scoring systems. As an advanced injury scoring System is developed in the future, the base deficit may have some significant role.

향류마치스 효과를 갖는 새로운 히스톤 Hl 단백질 (p961)의 횐쥐와 토끼에 대한 약물동태

우수경(Su Kyung Woo),윤민혁(Min Hyuk Yun),이재홍(Jae Heung Lee),권광일(Kwang Il Kwon) 대한약학회 2001 약학회지 Vol.45 No.4

A purified histone Hl protein, p961, which plays a role in mediating the condensation of DNA into chromatin, was recently proved as an arthritis-suppressing agent in the mouse CIA model. The pearmacokinetics of p961 was carried out in rats and rabbits. The rat's blood, bile and urine samples were semially collected from the femoral vein, common bile duct, and bladder respective1y; after bolus I.v. injection at low (10 mghg) and high (30 mg/mg) doses. The rabbit's blood samples were also collected from the marginal ear vein after bolus I.Y. injection at a dose 10 mg/kg. P961 and its major metabolite in the physiological samples were analyzed by reverse-phase HPLC using a Vydac C4 protein column and a multistep water-acetonitrile gradient containing 0.24% trifluoroacetic acid. The major pharmacokinetic parameters (AUC, Cmax, MRT t1/2, Vss and Cl) were estimated from the time course of plasma p961 and metabolite concentrations using WinNonlin. A two- compartment model was chosen for p961 as the most appropriate pharmacokinetic model. After I.v, injection of p961 at doses of 10 mghg and 30 mg/kg, more than 80% of p961 was removed rapidly from the plasma within 15 min. The plasma half-life of p961 in rats and rabbits was found not to exceed 12 min. p961 (22448.9 mot wt) was rapidly cleaved to 21612 mol wt fragment and the breakdown product appeared rapidly in the circulation with no lag phase. P961 and metabolite were not detected in rat urine and bile.